Archives

  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01

    • ALC-0315: LNP Role, Evidence, and Workflow

    2026-09-24

    ALC-0315: LNP Role, Evidence, and Workflow

    Executive Summary. ALC-0315 is an ionizable amino lipid used in lipid nanoparticle (LNP) formulations for nucleic acid drug delivery, according to the product information. Its stated chemical formula is C48H95NO5 and its molecular weight is 766.29 g/mol; the listing does not specify the measurement conditions for these values. The product specifications report water insolubility and solubility of at least 59.3 mg/mL in DMSO and 59.6 mg/mL in ethanol, with test conditions not stated. A separate in vivo PET report describes measurement of mRNA-encoded antigen expression, but those findings do not establish ALC-0315-specific performance. The cited report describes an eDHFR-based reporter approach.

    APExBIO identifies the product as SKU B8595. This article separates product specifications from study findings and practical workflow considerations. It does not treat a component-level description or imaging result as proof of a validated clinical formulation.

    Biological Rationale

    mRNA vaccines and other mRNA medicines rely on cells translating delivered genetic material into a protein. An LNP is a delivery vehicle that contains a lipid mixture and nucleic acid cargo. ALC-0315 is described as one ionizable amino lipid used in LNP formulations; its relevance is therefore at the formulation-component level, not as an antigen or standalone mRNA therapeutic.

    The product description attributes two delivery-related functions to ALC-0315: supporting intracellular transport and promoting cytoplasmic release of mRNA. These are product-level descriptions of intended formulation roles. They do not, by themselves, quantify uptake, endosomal escape, protein expression, or therapeutic effect for a particular recipe. Those outcomes depend on the complete formulation and experimental context, so users should distinguish the role assigned to a lipid from measured performance of a finished LNP.

    This distinction matters when interpreting in vivo imaging. A PET signal that reports antigen expression addresses the location and persistence of a protein product. Tracking an LNP or its nucleic acid is a different measurement. The in vivo PET report highlights this distinction: measurements of delivery vehicles or mRNA do not directly quantify the protein product encoded by the mRNA.

    Mechanism of Action of ALC-0315

    ALC-0315 is chemically identified as ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl) bis(2-hexyldecanoate). The product listing gives the formula C48H95NO5 and molecular weight 766.29 g/mol. These identifiers support reagent selection and record keeping, but they do not independently describe how a complete LNP behaves in cells.

    In the product’s stated application, ALC-0315 is a lipid nanoparticle component intended to contribute to nucleic acid delivery. The listing describes it as facilitating intracellular mRNA transport and cytoplasmic mRNA release. It does not provide a product-specific quantitative comparison against another lipid, an LNP recipe, or cell-type-specific delivery data. Avoid converting this general role into a claim that ALC-0315 alone guarantees cytoplasmic release or expression.

    For experimental interpretation, the relevant unit is the assembled formulation and its test conditions. Lipid identity is one controlled input; the other ingredients, preparation method, and biological model also need to be recorded. A formulation workflow should therefore report what was prepared and how it was tested, rather than treating the name of one lipid as a complete description of an LNP.

    Evidence & Benchmarks

    The evidence below has two different scopes. Product specifications describe the supplied reagent. The PET findings describe an mRNA-expression imaging approach and should not be read as a direct evaluation of ALC-0315.

    • The product listing identifies ALC-0315 as ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl) bis(2-hexyldecanoate), with formula C48H95NO5 and molecular weight 766.29 g/mol; analytical measurement conditions are not stated in the listing. (product information)
    • The listing reports solubility of at least 59.3 mg/mL in DMSO and at least 59.6 mg/mL in ethanol, and states that the compound is insoluble in water; temperature and assay conditions are not specified. (product information)
    • The listing recommends storage at −20°C and short-term use of prepared solutions; it does not state a validated solution shelf life or a universal stability interval. (product information)
    • The supplied product is listed at purity of at least 99.00%, with NMR, MS, and COA documentation identified as quality-control support; the listing does not state the purity calculation basis or assay conditions. (product information)
    • The PET reporter approach uses an 18 kDa Escherichia coli dihydrofolate reductase tag, eDHFR, genetically fused to mRNA-encoded antigen; the report describes trimethoprim as the PET radiotracer-binding partner. (Nature Reviews Bioengineering report)
    • The report describes tag and antigen expression in a 1:1 ratio while tagged genetic material remains in cells, and says unbound radiotracer is rapidly eliminated; these statements concern the reporter design, not ALC-0315 chemistry. (Nature Reviews Bioengineering report)
    • Whole-body PET imaging is reported to show transient antigen expression at the injection site and draining lymph nodes, disappearing within 7–20 days in the described experiments; the result is specific to the reported study models and constructs. (Nature Reviews Bioengineering report)

    Applications, Limits & Misconceptions

    ALC-0315 is relevant to research workflows that formulate LNPs for mRNA vaccine delivery or other nucleic acid drug delivery studies. It can be treated as a controlled lipid input while researchers evaluate particle properties and biological readouts. The product listing is not a substitute for a formulation protocol, product-specific efficacy data, or clinical authorization.

    The PET reporter work is relevant to a separate but connected question: where and for how long does an mRNA-encoded antigen appear in vivo? The report describes eDHFR-tagged antigen mRNA and PET imaging in female mice and male non-human primates. It also describes testing the imaging system with an approved COVID mRNA vaccine construct. These details support the potential use of imaging to study expression dynamics; they do not establish that ALC-0315 was the lipid used or that its performance was evaluated.

    Why this cross-domain matters, maturity, and limitations

    LNP formulation research and PET expression imaging answer complementary questions. Formulation studies characterize delivery materials and their biological performance, while the reported PET method tracks a tagged protein product in vivo. The connection is useful for study design because delivery and expression are not interchangeable endpoints. The cited report supports the imaging approach in its described preclinical models, but it does not establish routine clinical use, validate every mRNA construct, or provide evidence specific to ALC-0315.

    Common Pitfalls or Misconceptions

    • Water solubility: ALC-0315 is reported as insoluble in water. Do not assume it can be prepared as a simple aqueous stock; use the listed organic-solvent information as a starting point and verify compatibility in the intended workflow.
    • Component versus formulation: ALC-0315 is one lipid component, not a complete LNP. Its presence alone does not establish particle quality, delivery efficiency, or biological activity.
    • Reported solubility versus universal handling: The listed concentrations do not include solvent temperature or assay method. Do not treat them as a guaranteed solubility value under every laboratory condition.
    • PET signal versus lipid tracking: The described PET readout reflects reporter-linked antigen expression. It is not automatically a direct measurement of LNP biodistribution or ALC-0315 concentration.
    • Preclinical result versus clinical outcome: Expression timing reported in animal models does not establish a dosing schedule or duration of protection in people.

    Workflow Integration & Parameters

    Begin with the product identity and handling information, then define the formulation and biological questions independently. Record the lipid lot, solvent, preparation sequence, formulation composition, and downstream test conditions. The product information reports storage at −20°C and recommends short-term use for solutions; follow the current lot documentation for handling and avoid assuming a solution stability period that is not specified.

    For practical formulation development, keep the distinction between documented product parameters and workflow choices explicit. The numerical values below are listing specifications, not a validated LNP recipe. The recommendations about recording process variables are general experimental controls, not product-specific performance guarantees.

    Protocol Parameters

    • Identity: Use the stated chemical name and formula, C48H95NO5, to verify reagent records; the product listing reports a molecular weight of 766.29 g/mol. These are identity specifications, not evidence of performance in a particular formulation.
    • Solvent selection: The listing reports solubility of at least 59.3 mg/mL in DMSO and at least 59.6 mg/mL in ethanol, and insolubility in water. Measurement temperature and method are not reported, so confirm suitability for the intended preparation.
    • Storage: Store at −20°C as recommended in the product listing. The listing gives no numeric solution shelf life, so use prepared solutions short term and consult the lot-specific documentation.
    • Quality review: The listing states purity of at least 99.00% and identifies NMR, MS, and COA documentation. Review the supplied documentation for lot-specific details before recording the material as qualified.
    • Formulation records: Document the complete lipid composition, nucleic acid input, mixing method, and analytical readouts. These are workflow-recording recommendations; no universal ratios, mixing duration, or particle-size target are specified by the product listing.
    • Biological readout: Separate cellular uptake, intracellular mRNA transport, cytoplasmic release, and protein expression as distinct endpoints. Choose an assay suited to the question rather than inferring all stages from a single measurement.

    The linked guide ALC-0315: Practical LNP Formulation Workflow focuses on controlled organic-solvent formulation development. This article clarifies that its workflow framing should not be mistaken for water solubility or proof of a clinically validated formulation.

    The article ALC-0315 LNP Workflow: Mixing, QC, and Scale-Up emphasizes mixing and scale-up considerations. Here, the emphasis is narrower: product-specific specifications are separated from process variables, and no unsupported mixing setpoint is prescribed.

    Conclusion & Outlook

    ALC-0315 is a defined ionizable amino lipid used as an LNP component for nucleic acid delivery. Its reported identity, organic-solvent solubility, storage recommendation, and quality documentation provide practical starting points for research handling. They do not establish a complete formulation or predict its performance in a specific model.

    The PET report adds a measurement perspective: tagged mRNA can be used to follow antigen-expression dynamics in vivo in the described experimental settings. The defensible implication is that delivery-material characterization and protein-expression measurement can complement one another. Further conclusions about ALC-0315 itself require product-specific experiments that directly report the formulation, conditions, and biological endpoints.